-- A Phase III trial in chemotherapy-induced peripheral neuropathy (CPN)
is being conducted by the National Cancer Institute (NCI)-funded
Community Clinical Oncology Program. The double-blind, randomized
placebo-controlled study includes approximately 400 patients suffering
from painful CPN for at least 28 days following the conclusion of
chemotherapy. The primary endpoint of the 12-week trial is change in
average daily pain intensity scores from baseline to the endpoint.
This trial is currently enrolling patients.
-- A Phase IIb trial is underway in peripheral herpetic neuropathy. This
500-patient, placebo- and active-controlled trial will compare the
efficacy and safety of NP-1 vs. gabapentin and placebo. The primary
endpoint for this trial is the change in pain intensity over the four-
week duration of the trial. Preliminary results are expected early in
the second quarter of 2008.
About EpiCept Corporation
EpiCept is focused on unmet needs in the treatment of pain and cancer. The Company's broad portfolio of pharmaceutical product candidates includes several pain therapies in clinical development and a lead oncology compound for AML with demonstrated efficacy in a Phase III trial; a marketing authorization application for this compound is approaching a decision in Europe. In addition, EpiCept's ASAP technology, a proprietary live cell high- throughput caspase-3 screening technology, can efficiently identify new cancer drug candidates and molecular targets that selectively induce apoptosis in cancer cells. Two oncology drug candidates currently in clinical development that were discovered using this technology have also been shown to act as vascular disruption agents in a variety of solid tumors.
|SOURCE EpiCept Corporation|
Copyright©2007 PR Newswire.
All rights reserved